Show simple item record

dc.contributor.authorGaiotto, Tiziano
dc.contributor.authorRamage, Walter
dc.contributor.authorBall, Christina
dc.contributor.authorRisley, Paul
dc.contributor.authorCarnell, George W.
dc.contributor.authorTemperton, Nigel
dc.contributor.authorEngelhardt, Othmar G.
dc.contributor.authorHufton, Simon E.
dc.date.accessioned2021-02-04T16:27:00Z
dc.date.available2021-02-04T16:27:00Z
dc.date.issued2021-02-04
dc.date.submitted2020-09-17
dc.identifier.others41598-021-82356-4
dc.identifier.other82356
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/317172
dc.description.abstractAbstract: Influenza H7N9 virus continues to cause infections in humans and represents a significant pandemic risk. During the most recent 5th epidemic wave in 2016/17 two distinct lineages with increased human infections and wider geographical spread emerged. In preparation for any future adaptations, broadly reactive antibodies against H7N9 are required for surveillance, therapy and prophylaxis. In this study we have isolated a panel of nanobodies (Nbs) with broad reactivity across H7 influenza strains, including H7N9 strains between 2013 and 2017. We also describe Nbs capable of distinguishing between the most recent high and low pathogenicity Yangtze River Delta lineage H7N9 strains. Nanobodies were classified into 5 distinct groups based on their epitope footprint determined using yeast display and mutational scanning. The epitope footprint of Nbs capable of distinguishing high pathogenic (HP) A/Guangdong/17SF003/2016 from low pathogenic (LP) A/Hong Kong/125/2017 (H7N9) were correlated to natural sequence divergence in the head domain at lysine 164. Several Nbs binding to the head domain were capable of viral neutralisation. The potency of one nanobody NB7-14 could be increased over 1000-fold to 113 pM by linking two Nbs together. Nbs specific for distinct epitopes on H7N9 may be useful for surveillance or therapy in human or veterinary settings.
dc.languageen
dc.publisherNature Publishing Group UK
dc.rightsAttribution 4.0 International (CC BY 4.0)en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en
dc.subjectArticle
dc.subject/631/1647
dc.subject/631/61
dc.subject/631/154
dc.subject/631/250
dc.subject/631/337
dc.subjectarticle
dc.titleNanobodies mapped to cross-reactive and divergent epitopes on A(H7N9) influenza hemagglutinin using yeast display
dc.typeArticle
dc.date.updated2021-02-04T16:26:59Z
prism.issueIdentifier1
prism.publicationNameScientific Reports
prism.volume11
dc.identifier.doi10.17863/CAM.64283
dcterms.dateAccepted2021-01-15
rioxxterms.versionofrecord10.1038/s41598-021-82356-4
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
dc.identifier.eissn2045-2322
pubs.funder-project-idBiomedical Advanced Research and Development Authority (HHSO100201300005C, HHSO100201300005C, HHSO100201300005C, HHSO100201300005C, HHSO100201300005C, HHSO100201300005C)


Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's licence is described as Attribution 4.0 International (CC BY 4.0)